Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)
Recruiting · NCT03792919 · Interventional (participants receive a specific treatment) · Lead sponsor: Humanity & Health Medical Group Limited
View the official record on ClinicalTrials.gov →Interventions studied
Keep current treatment (anti-HBV neucleos(t)ides)Stop current treatment (anti-HBV neucleos(t)ides)
What this trial is about
To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- HBsAg positive, HBeAg negative, antibody to HBeAg-positive;
- Stable administration of anti-HBV neucleos(t)ides analogue mono therapy for at least more than one and a half year;
- Demonstration of undetectable HBV DNA on three occasions, each at least 6 months apart, which is consistent with the APASL stopping rule;
- Patients read, understand the consent form, and signed the study consent.
Exclusion criteria
- Patient with other liver diseases;
- Patient with concurrent hepatitis viruses or HIV infection;
- Patients are reluctant to stop their anti-HBV treatment.
Where it is running
1 location listed.
- Humanity & Health Research Centre - Hong Kong, Hong Kong SAR, Hong Kong